Humacyte, Inc. (HUMA), Friday said that the Food and Drug Administration or FDA has granted approval for SYMVESS for use in adults as a vascular conduit for extremity arterial injury.
Humacyte's Biologics License Application (BLA) included positive results from the V005 pivotal Phase 2/3 study, as well as real-world evidence from the treatment of wartime injuries in Ukraine under a humanitarian aid program.
In clinical testing SYMVESS was observed to have high rates of patency, or blood flow, and low rates of amputation and infection.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.